Endologix, a developer of minimally invasive treatments for aortic disorders, has entered into a development and exclusive license agreement with Evasc Medical Systems, for its balloon expandable stent technology.
The patented stent is made from cobalt chromium and is pre-mounted on an angioplasty balloon catheter for ease-of-use.
The fenestrated stent graft will be a new aortic extension designed to be used with Endologix’s Powerlink main body bifurcated stent grafts.
It is designed to provide an off-the-shelf, endovascular treatment option for short neck and juxtarenal abdominal aortic aneurysms (AAA), which require the graft to extend above the renal arteries in order to achieve proper fixation and sealing.
The balloon expandable stent graft will be used to branch the fenestrated stent graft into the renal arteries, allowing normal blood flow to the kidneys.
Endologix president and chief executive officer John McDermott said that this patented balloon expandable stent technology will be integrated into fenestrated stent graft device, which will expand the endovascular AAA market to include short aortic necks and aneurysms that extend up above the renal arteries.
Evasc CEO Ian McDougall said that they are extremely pleased to have entered into this license and development agreement with Endologix. Endologix has a respected reputation in the endovascular market and will be a strong ally for bringing this balloon expandable stent graft to market and achieving market penetration.